Related Experiment Video
Updated: Jul 12, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido
Shina Oranratanaphan1, Surasak Taneepanichskul
1Department of Obstetrics and Gynecology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Rama IV Rd, Bangkok 10330, Thailand.
Background:
Oral contraceptive is the most commonly used method of fertility control. Yasmin is a combination of a novel progestogen with anti-androgenic and anti-mineralcorticoid activities (3 mg Drospirenone (DRSP) and 30 microg ethinylestradiol (EE)). It has been shown in many clinical trials that Yasmin is an efficacious oral contraceptive, lacking undesired effects as with other oral contraceptives such as weight gain. However the effects of Yasmin on sexual desire and libido have not been intensively investigated so far
Objective:
Investigate the effects of Yasmin on sexual desire, libido and changes in the free androgen index (FAI) compare to Meliane (75 microg gestodene + 20 microg ethinylestradiol).
Material And Method:
The authors' report the results of a double blind randomized controlled study using a translated version of the Female Sexual Function Index questionnaire (FSFI) for the assessment of the sexual function. The free androgen index was calculated from measurements of testosterone and sexual hormone binding globulin.
Result:
The result shows statistically significant improvements regarding sexual desire, arousal and overall satisfaction in the Yasmin group. Additionally, an increased frequency of orgasms in the Meliane group was reported. Statistically significant differences between the two treatments regarding changes in the FSFI score and changes in the free androgen index have not been observed.
Conclusion:
The novel oral contraceptive containing drospirenone (Yasmin) and the non-anti-androgenic progestin containing oral contraceptive (Meliane) do not show unfavorable effects on sexual response and libido.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Blind Procedures
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Dose-Response Relationship: Potency and Efficacy
Bioavailability Study Design: Healthy Subjects Versus Patients
Blinding